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Abstract
Objective: Posterior reversible leukoencephalopathy syndrome (PRES) is characterized by headache, 
altered mental status, cortical blindness, and seizures associated with neuroradiological findings. It involves 
predominantly white matter of the parieto-occipital lobes. Several medications and disorders play a role in 
the etiology of PRES. In this study, we aimed to show how the prognosis of PRES in hematological dis-
eases of childhood might be according to the etiological factors.
Materials and Methods: Here, we report PRES in six patients, aged 4 to 14 years, with diagnoses of leuke-
mia and aplastic anemia. 
Results: Suggested causes in our patients were chemotherapeutics, hypertension, infection and antimicro-
bial drug administration, tumor lysis syndrome, acute renal failure and hemodialysis, immunosuppressive 
drug administration, and hypomagnesemia. One of the patients died of sepsis, renal failure and pulmonary 
hemorrhage and another died of relapse after total recovery from PRES. The other four patients are under 
follow-up without problems. 
Conclusion: We suggest that PRES can recover fully with early diagnosis and treatment whereas it can show 
poor prognosis depending on the etiology. (Turk J Hematol 2010; 27: 168-76)
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Özet
Amaç: Posterior geri dönüşümlü lökoensefalopati sendromu (PGDLS) nöroradyolojik bulgularla birlikte 
baş ağrısı, bilinç değişiklikleri, kortikal körlük ve nöbet ile seyreden bir sendromdur. Hastalık ağırlıklı 
olarak parieto-oksipital lobların beyaz cevherini tutar. Çeşitli ilaçlar ve hastalıklar PGDLS etiyolojisinde Introduction
Posterior reversible leukoencephalopathy syn-
drome (PRES) is a disorder that typically presents with 
headache, nausea and vomiting, visual disturbances, 
a disturbed level of consciousness, seizures, and 
occasionally focal neurologic deficits often in the set-
ting of accelerated hypertension [1]. The entity has 
become increasingly recognized over recent years, 
with the term PRES first being used in 1996 [1]. Some 
of the suspected factors in the etiology of this syn-
drome are sickle cell disease, severe hypertension, 
solid organ and bone marrow transplantation, acute 
renal failure, tumor lysis syndrome (TLS), immuno-
suppressive/cytotoxic drugs, and chemotherapeutic 
agents [2-5]. The pathophysiology of this complex 
syndrome is still unknown. In uncomplicated patients, 
magnetic resonance imaging (MRI) of the brain illus-
trates edema primarily in the cortex and subcortical 
white matter of posterior brain regions, such as the 
occipital lobes and posterior parietal lobes. These 
findings generally resolve with normalization of 
blood pressure or discontinuation of the offending 
drugs [6]. Although recognized to occur in pediatric 
patients, PRES has not been well evaluated in this 
age group [7]. The aim of this study was to analyze a 
group of pediatric patients with hematologic disorders 
who developed PRES. We also aimed to identify pos-
sible predisposing factors and describe the common 
clinical and radiographic features.
Materials and Methods
Patient 1
A five-year-old male had been diagnosed with 
T-cell acute lymphoblastic leukemia (ALL) (initial 
white blood cell (WBC) count: 450×109/L), and 
ALL-BFM 90 chemotherapy protocol had been start-
ed at a local center. He had been given oral low-
dose steroid and intrathecal methotrexate. Although 
alkali hydration and oral allopurinol for TLS prophy-
laxis were administered, he had developed acute 
renal failure after administration of intravenous vin-
cristine. Biochemical analysis at that time revealed 
the following values: blood urea nitrogen (BUN): 83 
mg/dl (normal range, 6-21 mg/dl), creatinine: 1.27 
mg/dl (normal range, 0.5-1.0 mg/dl), sodium (Na): 
130 mmol/L (normal range, 135-146 mmol/L), potas-
sium (K): 7.1 mmol/L (normal range, 3.5-5.2 
mmol/L), uric acid: 5.2 mg/dl (normal range, 2.5-6 
mg/dl), calcium (Ca): 6.2 mg/dl (normal range, 8.5-
10.5 mg/dl), and phosphorus: 16 mg/dl (normal 
range, 3-6 mg/dl). He had developed TLS and was 
referred to our hospital for hemodialysis on the third 
day of chemotherapy. The physical examination at 
admission revealed normal blood pressure (90/60 
mmHg), confusion, lethargy, and abdominal disten-
tion due to hepatomegaly. Complete blood count 
showed hemoglobin (Hb): 7.4 g/dl, WBC count 
40.4×109/L, and platelet count: 54×109/L, and bio-
chemical analysis revealed BUN 85 mg/dl, creatinine 
1.3 mg/dl, Ca 5.6 mg/dl, phosphorus 11.9 mg/dl, uric 
acid 9.7 mg/dl, Na 135 mmol/L, K 4 mmol/L, total 
protein 5.7 g/dl (normal range, 6-8 g/dl), albumin 3.3 
g/dl (normal range, 3.5-5.5 g/dl), and total choles-
terol 160 mg/dl (normal range 140-200 mg/dl). For 
the treatment of TLS, intravenous alkali hydration, 
allopurinol and calcium-acetate were administered. 
He also had hemodialysis treatment six times until 
his biochemical values returned to normal. Imipe-
nem and amikacin were started because of neutro-
penic fever. On the fourth day of hospitalization, 
vomiting, headache, focal seizures, and paresis on 
the right arm were observed. The physical examina-
rol oynar. Bu çalışmada, çocukluk çağı hematolojik hastalıklarında altta yatan nedenlere göre PGDLS’nun 
nasıl seyrettiğini göstermeyi amaçladık. 
Yöntemve Gereçler: Burada, yaşları 4 ile 14 arasında olan, lösemi ve aplastik anemi tanıları ile izlenen 
PGDLS’lu 6 hastayı sunduk.
Bulgular: Hastalarımızda kemoterapotikler, hipertansiyon, infeksiyon, antimikrobiyal ilaç kullanımı, 
tümör lizis sendromu, akut böbrek yetmezliği, hemodiyaliz, immünsüpresif ilaç kullanımı ve hipomagne-
zemiyi PGDLS nedenleri olarak tespit ettik. Hastalarımızdan birini sepsis, böbrek yetmezliği ve pulmoner 
hemaroji nedenleriyle, bir diğerini ise PGDLS tamamen düzeldikten sonra relaps nedeniyle kaybettik. 
Diğer dört hastamız herhangi bir problemi olmaksızın izlenmektedir.
Sonuç: PGDLS erken tanı ve tedavi ile tamamen düzeltilebilir bir hastalık olmasına rağmen altta yatan 
nedene bağlı olarak kötü seyirli de olabilen bir sendromdur. (Turk J Hematol 2010; 27: 168-76)
Anahtar kelimeler: Akut lösemi, aplastik anemi, posterior geri dönüşümlü lökoensefalopati sendro-
mu, tümör lizis sendromu
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hemiparesis. Brain MRI disclosed bilateral hyperin-
tense signal changes at the bilateral frontoparietal, 
occipital and temporal areas on fluid-attenuated inver-
sion recovery (FLAIR) and T2-weighted images, con-
sistent with vasogenic edema. Diffusion-weighted 
imaging (DWI) confirmed the presence of vasogenic 
edema (Figure 1a). Electroencephalogram (EEG) 
showed epileptiform activity in the right temporal 
lobe. Phenytoin was started; however, due to insistent 
seizures, phenobarbital was added to the treatment. 
On the eighth day of the treatment, the neurological 
findings began to regress. The follow-up MRI per-
formed 15 days after the first seizure showed almost 
complete regression of the initial findings (Figure 1b). 
His seizures did not recur, so phenobarbital and phe-
nytoin were stopped five and six weeks after the initia-
tion of the antiepileptic therapy, respectively. He com-
pleted the chemotherapy protocol three years ago, 
and has had no problems over the last four years. 
Patient 2
A 12-year-old male had been admitted to a local 
center with the diagnosis of abdominal Burkitt lym-
phoma. The physical examination had revealed a 
mass of 10x10 cm in diameter at the upper right 
quadrant of the abdomen. His blood pressure was 
normal. Complete blood count at the time showed 
Hb: 9.4 g/dl, WBC count: 14.7x109/L, and platelet 
count: 613x109/L. Biochemical analysis was normal 
except for lactate dehydrogenase (LDH) (3235 U/L 
[normal range: 120-300 U/L]) and aspartate ami-
notransferase (AST) (65 U/L [normal range: 0-40 
U/L]). Following the intravenous alkali hydration 
and oral allopurinol, he had been given intravenous 
cyclophosphamide. Immediately after cyclophos-
phamide treatment, he developed anuria and hyper-
tension (150/100 mmHg) and tumor lysis syndrome 
(TLS) within 24 hours. The biochemical analysis at 
the time revealed BUN 53 mg/dl, creatinine 2.25 mg/
dl, Ca 7.6 mg/dl, phosphorus 13 mg/dl, uric acid 8.4 
mg/dl, Na 131 mmol/L, K 3.5 mmol/L, total protein 
5.9 g/dl, and albumin 3.2 g/dl. After administration of 
captopril and furosemide, the patient was referred 
to our hospital for hemodialysis treatment. At admis-
sion, his blood pressure was 145/95 mmHg. The 
complete blood count revealed Hb 9.1 g/dl, WBC 
count 13.3x109/L and platelet count 683x109/L. 
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Figure 1. There are hyperintensities on both frontal and parietal white matter, consistent with vasogenic edema on initial axial FLAIR im-
age (A). There are also similar signal changes in temporal lobes (not shown). On follow-up MRI, the FLAIR image shows regression of the 
edema at the frontal and parietal lobes (B)Biochemical analysis showed BUN 23 mg/dl, creati-
nine 3.73 mg/dl, Na 135 mmol/L, K 3.5 mmol/L, uric 
acid 1.3 mg/dl, Ca 8.7 mg/dl, phosphorus: 4.1 mg/dl, 
magnesium (Mg) 1.5 mg/dl, total protein: 5.7 g/dl, 
albumin: 2.9 g/dl, AST 25 U/L, alanine aminotrans-
ferase (ALT) 10 U/L, and LDH: 693 U/L. Amlodipine 
was added to the anti-hypertensive therapy due to 
persisting high blood pressure. Renal function had 
partially improved. He received hemodialysis treat-
ment 12 times over 20 days, and his NHL BFM 90 
course AA protocol (doses adjusted for creatinine 
clearance) was started due to the enlargement of 
the abdominal mass. At the time, he developed 
febrile neutropenia and intravenous broad-spec-
trum antibiotics (cefepime and amikacin) were 
started. On the second day of the antibiotic treat-
ment, generalized tonic-clonic seizure and lateral 
deviation on the left eye were observed. His general 
status was poor on his physical examination with 
continuing high blood pressure. He had hyperreac-
tive deep tendon reflexes (DTR) with additional 
clonus on his right lower extremity. His biochemical 
analysis disclosed the following values: BUN: 41 
mg/dl, creatinine: 1.97 mg/dl, Mg: 0.9 mg/dl (normal 
range, 1.6-3 mg/dl), albumin: 2.9 mg/dl, Na: 132 
mmol/L, K: 3.9 mmol/L, Ca: 9.4 mg/dl, phosphorus: 
3 mg/dl, AST: 27 U/L, ALT: 16 U/L, and total choles-
terol: 162 mg/dl. Brain MRI showed bilateral patchy 
increase in signal intensity of the cortical and sub-
cortical areas on the parietal and frontal lobes on 
FLAIR images (Figure 2a). Dexamethasone and 
phenytoin were started for his convulsions. Due to 
persistent seizures, valproic acid was added to the 
treatment; however, the seizures were refractory to 
both agents so additional midazolam and thiopental 
infusions were started. The brain MRI performed one 
week later showed progressive findings on FLAIR 
and T2-weighted images. Although the lesions were 
increased in distribution, no evidence of cytotoxic 
edema was found on DWI (Figure 2b, 2c). Twenty 
days after beginning anti-epileptic therapy, the patient 
died due to sepsis, renal failure and pulmonary hem-
orrhage.
Patient 3
A 10-year-old male had been admitted to a local 
center with polyuria and swelling of the eyelids. 
Blood pressure had been measured as 130/90 
mmHg on physical examination. Complete blood 
count had shown Hb: 10.6 g/dl, WBC count: 
43.2x109/L, and platelet count: 89x109/L with 65% 
blasts on peripheral blood smear. Diffuse L-3 type 
blastic infiltration was present on bone marrow 
smear and biopsy. Biochemical analysis had shown 
BUN: 49.7 mg/dl, creatinine: 1.4 mg/dl, uric acid: 
15.6 mg/dl, total protein: 6.1 g/dl, albumin: 3.8 g/dl, 
ALT: 99 U/L, AST: 129 U/L, Na: 133 mmol/L, K: 4.1 
mmol/L, Ca: 9.3 mg/dl, phosphorus: 3.1 mg/dl, and 
Mg: 2.1 mg/dl. With these findings, the patient had 
been diagnosed with ALL and acute renal failure 
due to TLS. Alkali hydration, allopurinol and low-
dose dexamethasone (0.5 mg/d) were adminis-
tered. Despite this therapy, the patient’s WBC count 
had increased, and blood pressure had risen, and 
he developed dyspnea secondary to hypervolemia 
and impaired renal functions. The patient was then 
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Figure 2. Axial initial FLAIR image shows mild signal increase on the frontal and parietal lobes (A). On follow-up MRI, FLAIR images 
show severe progression of the lesions on bilateral frontal, parietal and temporal lobes and new lesions are seen on bilateral cerebellar 
hemispheres (B,C)referred to our hospital for hemodialysis. The bio-
chemical analysis at that time revealed BUN: 31 mg/
dl, creatinine: 2.75 mg/dl, uric acid: 9.5 mg/dl, total 
protein: 6.1 g/dl, albumin: 3.3 g/dl, ALT: 30 U/L, AST: 
61 U/L, Na: 128 mmol/L, K: 3.2 mmol/L, Ca: 8.1 mg/
dl, phosphorus: 8.5 mg/dl, Mg: 1.5 mg/dl, and LDH 
3080 U/L. Low-dose dexamethasone (1 mg/d) and 
allopurinol were started. He received hemodialysis 
treatment 4 times over 4 days. After hemodialysis, 
the patient’s blood pressure levels normalized. He 
was given NHL BFM 95 prephase block and imme-
diately after the prephase, Course AA block was 
started. On the third day of his chemotherapy, he 
developed visual disturbance, headache and vomit-
ing before etoposide and cytarabine treatment. At 
the time, his blood pressure was 150/95 mmHg. Six 
hours later he had generalized tonic-clonic seizures. 
On MRI, FLAIR images showed diffuse signal 
increase in the cortex and subcortical white matter 
of the bilateral frontal, parietal and temporal lobes, 
and also in bilateral cerebellar hemispheres, which 
was demonstrated as vasogenic edema on DWI. 
Serum methotrexate level (42nd hour of methotrex-
ate infusion) was 2.4 μmol/L. EEG was normal. 
Chemotherapy was stopped and phenytoin was 
given. Fifteen days after PRES, the patient had no 
neurological problems and his chemotherapy was 
re-started. MRI performed two months after the 
diagnosis showed disappearance of all of the 
lesions; no evidence of signal changes was found. 
Three months after PRES, phenytoin dose was 
decreased gradually and then stopped.
Patient 4
A 14-year-old girl had been diagnosed with AML-
M2 at a local center. AIE block of AML BFM 93 treat-
ment protocol including cytosine arabinoside, ida-
rubicin and etoposide had been started. Due to 
febrile neutropenia and invasive pulmonary asper-
gillosis, voriconazole, meropenem and metronida-
zole had been administered. She had developed 
visual disturbance and weakness in both lower 
extremities, in addition to cerebellar findings (hypo-
metria, incompetency in knee-toe test). She devel-
oped generalized convulsions three times after 
cerebellar findings. The patient had been normo-
tensive during this period. At the time, Hb was 9.2 g/
dl, WBC count was 0.82x109/L and platelet count 
was 21.0x109/L; the biochemical analysis showed 
total cholesterol of 88 mg/dl, Ca 6.9 mg/dl and albu-
min 2.2 g/dl. The patient was referred to our hospital 
with these findings for intensive care. Brain MRI 
revealed symmetrical hyperintensities in the bilat-
eral thalami and frontal lobes on FLAIR and 
T2-weighted sequence. As this kind of localization is 
rare, she was diagnosed as atypical PRES. Her EEG 
was normal. Phenytoin was started initially; how-
ever, due to persistent convulsions, phenobarbital 
was added. From the 10th day of the anti-epileptic 
treatment, neurologic symptoms started to improve 
and at the end of the second week, the symptoms 
had totally regressed. One month later, the follow-
up MRI showed marked regression of the lesions. 
The neurologic symptoms and the invasive fungal 
infection had regressed, so the chemotherapy pro-
tocol was continued. Anti-epileptic treatment was 
stopped at the 4th month. Her chemotherapy was 
completed and she has been in remission for the 
last six months.
Patient 5
A four-year-old male was given St. Jude Total XIII 
I/H risk chemotherapy protocol with the diagnosis 
of Pre-B ALL. On the 15th day of induction therapy, 
vincristine, prednisolone, daunorubicin, and 
L-asparaginase were administered. Seven days after 
this treatment, generalized tonic-clonic seizure had 
occurred. The patient was monitored with mechan-
ical ventilation because of status epilepticus. The 
physical examination revealed blood pressure of 
125/95 mmHg. His Hb was 8.7 g/dl, WBC count 
3.2x109/L and platelet count 112x109/L; the bio-
chemical analysis was normal. On cranial MRI, 
there were asymmetric cortico-subcortical hyperin-
tense signal changes at bilateral occipital and pari-
etal areas on FLAIR images. DWI also showed 
vasogenic edema. EEG revealed bilateral temporal 
irregular background activity. The chemotherapy 
protocol was stopped and carbamazepine was 
administered. On the 7th day of the anti-epileptic 
treatment, the neurological symptoms recovered. 
Two months after the anti-epileptic treatment, fol-
low-up cranial MRI revealed that the lesions had 
totally regressed. His seizures did not re∆cur, so the 
anti-epileptic treatment was stopped and the chem-
otherapy was continued. At the 93rd week of the 
maintenance chemotherapy, he developed a bone 
marrow relapse. During the administration of 
relapse protocol, he died of sepsis.
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A 13-year-old girl had received a treatment proto-
col consisting of anti-thymocyte globulin, cyclospo-
rine, danazol, prednisolone, and filgrastim for severe 
acquired aplastic anemia. During the 2nd month of 
the treatment, headache, contractions of the right 
arm and staring at a point had developed. Physical 
examination revealed blood pressure of 140/85 
mmHg and DTR were hyperactive. Complete blood 
count showed Hb: 7.38 g/dl, WBC count: 7.2x109/L 
and platelet count: 149x109/L. Biochemical analysis 
revealed BUN 21 mg/dl, creatinine 0.49 mg/dl, Ca 
8.5 mg/dl, Na 132 mmol/L, K 4.4 mmol/L, AST 30 
U/L, ALT 188 U/L, gamma-glutamyl transpeptidase 
(GGT) 34 U/L, alkaline phosphatase (ALP) 217 U/L, 
total cholesterol 186 mg/dl, and Mg 1.5 mg/dl. Brain 
MRI showed hyperintense signal changes on the 
posterior-inferior part of the right cerebellar hemi-
sphere and right parietal subcortical white matter at 
the level of the vertex on FLAIR and T2-weighted 
sequences, which were confirmed to be vasogenic 
edema on DWI. During this period, the serum level 
of cyclosporine was found to be high (530 ng/ml; 
normal range: 100-400 ng/ml) and it was then 
stopped. Phenytoin was started for the convulsions 
and following the treatment, there was no convul-
sion recurrence. The brain MRI performed five 
months after anti-epileptic treatment showed that 
edema had regressed; however, hemorrhage was 
observed in the subcortical white matter of the 
bilateral frontal lobes and right posterior parietal 
and left occipital lobes on gradient-echo images. 
The control EEG was normal. During the follow up, 
phenytoin treatment was stopped after one year. 
The patient has been in partial remission for the last 
three years.
Results and Discussion
Various factors have been defined in the etiology 
of PRES. The most common factors are immuno-
suppressive drugs (cyclosporine, anti-thymocyte 
globulin, tacrolimus, rituximab, interferon), and 
chemotherapeutic agents (methotrexate, 
L-asparaginase, adriamycin, cyclophosphamide, 
cytosine arabinoside, vincristine) [2,4,7,8-11]. Sickle 
cell disease, hypertension, acute blood pressure 
changes, renal failure, TLS, infection, sepsis, shock, 
and organ transplantation are some factors that can 
also cause PRES [3,5,12-15]. The exact etiopatho-
genesis of posterior leukoencephalopathy syn-
drome is still unknown. Two opposing hypotheses 
are commonly cited, but the issue is controversial. 
The more popular theory suggests that severe 
hypertension exceeds the limits of autoregulation, 
with injury to the capillary bed and hyperperfusion 
leading to breakthrough brain edema [16]. Another 
theory suggests that hypertension leads to cerebral 
autoregulatory vasoconstriction, ischemia and sub-
sequent cytotoxic edema and then extracellular 
edema [1,17].
On computerized tomography (CT)/MRI, the 
brain typically demonstrates focal regions of sym-
metric hemispheric edema. The parietal and occip-
ital lobes are most commonly affected, followed by 
the frontal lobes, the inferior temporal-occipital 
junction and the cerebellum [10]. Lesion conflu-
ence may develop as the extent of edema increas-
es. DWI was instrumental in establishing and con-
sistently demonstrating that the areas of abnormal-
ity represent vasogenic edema [18]. Focal/patchy 
areas of PRES vasogenic edema may also be seen 
in the basal ganglia, brain stem, and deep white 
matter [18-20]. In our patients, frontal lobe (n=4), 
parietal lobe (n=5), occipital lobe (n=4), temporal 
lobe (n=2), cerebellum (n=2), and thalamus (n=1) 
were involved. (Table 1) The above-mentioned 
abnormalities were bilaterally symmetric in five 
patients (not in Case 6). Research indicates that 
imaging abnormalities in posterior leukoencepha-
lopathy syndromes are often symmetrical; however, 
asymmetrical involvement is not unusual [1,10].
In our patients, chemotherapeutics (n=5), hyper-
tension (n=5), infection and antimicrobial drug 
administration (n=3), acute renal failure and hemo-
dialysis with TLS (n=3), and immunosuppressive 
drug administration and hypomagnesemia (n=1) 
were suggested to be the causes of PRES (Table 2). 
The blood pressures according to age, sex and 
height of all our patients were high in our patient 
group with the exception of Case 4. PRES may also 
develop and reverse in the face of systemic toxicity 
but in the absence of hypertension. In 20-30% of 
patients who develop PRES, blood pressure is 
essentially normal at toxicity [8]. The blood pres-
sure of Case 4 was in normal ranges. In this patient, 
intravenous and intrathecal cytosine arabinoside, 
idarubicin, etoposide, and antibiotics for the treat-
ment of febrile neutropenia may have been the 
causative factors for PRES.
Infection and/or inflammation are some other 
factors accused in the pathogenesis of PRES. The 
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Table 1. Distribution of lesions with regard to the brain lobes on initial and follow-up magnetic resonance imagings
Case Parietal  Occipital  Frontal  Temporal  Cerebellar  Talamus  Control  MRI
1   Bilateral   Bilateral   Bilateral   Bilateral   N  N  Regression
2  Bilateral   Bilateral  Bilateral  N  N  N  No regression
3  Bilateral   Bilateral   Bilateral   Bilateral   Bilateral   N  N
4  N   N  Bilateral  N  N   Bilateral   N
5 Bilateral  Bilateral    N  N  N  N  N
 asymmetric  asymmetric
6  Right   N   N   N  Right  N  Regression
           (New  hemorrhagic  areas)
MRI: magnetic resonance imaging; N: normal
Table 2. Demographic and clinical data for the 6 patients of posterior leukoencephalopathy syndrome
Case  Age   Sex  Disease  Medication  Mean arterial BP  TLS  Infection  EEG  Treatment  Signs and  Outcome
  (Year)        syst/diast  (mmHg)        symptoms 
1   5  M  T-ALL  Prednisolone  125/85*  +  +  AN  Phenytoin  Vomiting  Remission
        Vincristin,            Headache  without
        MTX  (I.T.)          Focal  seizure  neurologic
        Allopurinol          Paresis  on  the  sequel
        Ca-asetat,            right  arm
       Imipenem       
       Amicasin
2  12  M  Burkitt   Prednisolone Cytarabine,  150/100*  +  +  NA  Phenytoin  GTC  Died due to
      lymphoma   Ifosfamid, Etoposid,           Dexhamethasone  Lateral  sepsis, renal
         Cefepime, Amikacin,          Valproic acid  deviation on the  failure and
        Amlodipine,  Captopril,        Midazolam  left  eye  pulmonary
        Allopurinol        Thiopental  Hyperactive    hemorrhage
                  DTR
                  Clonus  on  right 
                  lower  extremity
3  10  M  ALL L-3  Dexametasone,   150/95*  +  -  N  Phenytoin  Vomiting  Chemotherapy
        Ifosfamid,  Vincristin          Headache  continues
        MTX, MTX (IT),             GTC  without
        Cytarabine  (IT),            neurologic
        Prednisolone  (IT)            sequel
4  14  F  AML  Cytarabine Idarubicin,   100/60  -  +  N  Phenytoin  Visual  Remission
        Etaposid,  Meropenem,        Phenobarbital  disturbance  without
        Metronidazole,            Hypometry,  neurologic
        Voriconazole          Incompetency  sequel
                     in knee-toe test
                  G T C    
5  4  M  Pre-B ALL  Prednisolone,   125/95*  -  -  AN  Carbamazepine  GTC  Died due
        Vincristin,              to  sepsis
       Daunorubicin,
       L-asparaginase
6  13  F  Aplastic   Cyclosporin, ATG,  140/85*  -  -  N  Phenytoin  Headache,   Partially 
      anemia  G-CSF, Danazol,             Contractions  remission
        Prednizolone          at  the  right  without 
                    arm, Staring to   neurologic
                    a point, Hyperactive,   sequel
                  DTR 
M: male; F: female; ALL: Acute lymphoblastic leukemia; AML: Acute myeloblastic leucemia; ATG: antitimocyte globulin; BP: blood pressure; Ca: calcium; DTR: deep tendon reflex; 
EEG: electroencephalogram; G-CSF: granulocyte- colony stimulating factor; GTC: generalized tonic-clonic convulsions; IT: intrathecal; NA: non available; AN: abnormal; N: normal; 
MTX: methotrexate; TLS: tumor lysis syndrome
* Increased blood pressure according to age, sex and heightseptic shock response likely reflects systemic toxicity 
similar to systemic inflammatory response syndrome 
or multiorgan dysfunction syndrome and bactere-
mia, or endotoxins/exotoxins are considered as 
potential triggers [21,22]. Cytokine response (tumor 
necrosis factor [TNF]-α, interleukin [IL]-1) plays a 
critical role in development of this effect [23]. Gram-
positive organisms are commonly obtained in infec-
tion/sepsis/shock-associated PRES [14]. In our 
study, three of our patients had infection. Case 4 
was in febrile neutropenia, receiving antibiotics and 
antifungals after the treatment, when she devel-
oped neurologic findings. However, during this 
period, all the cultures were negative.
An alternative mechanism of PRES also implicates 
endothelial dysfunction, such a notion underpinning 
the treatment of affected individuals with immuno-
suppressive therapy, mainly cyclosporine [1]. 
Immunosuppressive agents could damage the 
blood-brain barrier by various means: direct toxic 
effects on the vascular endothelium, vasoconstric-
tion caused by elaboration of endothelin and micro-
thrombosis [1]. The situation for bone marrow 
transplant recipients who feature cyclosporine neu-
rotoxicity may be related to abnormalities of the 
blood-brain barrier, increased blood pressure and 
renal failure prior to the onset of various neurologi-
cal symptoms [13]. Under most circumstances, the 
neurological symptoms and signs associated with 
cyclosporine use are reversible when the drug’s 
administered dosage is decreased or stopped, but 
symptoms may recur when the drug is reintro-
duced. Although neurotoxicity appears to be more 
frequent when blood cyclosporine levels are sub-
stantially elevated, neurotoxicity may also occur 
when the drug is administered within the normal 
therapeutic range [1]. Hypocholesterolemia and 
hypomagnesemia are found in more than 50% of 
patients with cyclosporine neurotoxicity [2]. The 
steroids administered simultaneously with 
cyclosporine can also aggravate the neurologic 
complications of cyclosporine [9]. In Case 6, blood 
cyclosporine level (530 ng/ml) was only marginally 
above the recommended normal range (200-400 
ng/ml). This patient also had a low magnesium level 
(1.5 mg/dl); however, the cholesterol level was nor-
mal. Additionally, this patient was receiving both 
prednisolone and cyclosporine, and both may have 
contributed to PRES. 
There are reports on the development of PRES in 
patients with TLS. TLS causes hypertension and 
various electrolyte imbalances, which result in 
PRES. Recent literature reports PRES patients sec-
ondary to TLS, seen after chemotherapy administra-
tion for hematologic malignancies, similar to our 
patients (Cases 1, 2, and 3) [3,10,11].
In summary, PRES is a multi-factorial syndrome. 
As in our patients, one or more factors such as TLS, 
chemotherapeutics, immunosuppressive drugs, and 
sepsis may cause PRES. This syndrome usually 
improves without any complications. However, it 
may progress to irreversible neurologic deficits, 
even death, depending on the severity of the prima-
ry disease and delays in diagnosis and treatment.
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